Belviq Lawsuits For Pancreatic Cancer, Colon Cancer, Rectal Cancer, Lung Cancer
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
In February 2020 there was a Belviq recall due to cancer cases observed in a Belviq safety clinical trial. The Belviq FDA Drug Safety Communication announcing this Belviq recall, “FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market”, noted that excess cases of pancreatic cancer, colon cancer, rectal cancer, and lung cancer were observed. This Belviq recall has resulted in Belviq lawsuits being filed against the responsible pharmaceutical company, Eisai Inc.
The Data Summary section of the Belviq FDA Drug Safety Communication set forth these findings from the Belviq safety clinical trial:
Imbalances in specific cancers including pancreatic, colorectal, and lung contributed to the observed overall imbalance in cancer cases. There was no apparent difference in the incidence of cancer over the initial months of treatment, but the imbalance increased with longer duration on [Belviq (lorcaserin)].
According to the FDA, these are some of the specific types of cancer associated with Belviq:
- Pancreatic Cancer
- Colorectal Cancer
- Colon Cancer
- Rectal Cancer
- Lung Cancer
Our law firm is investigating possible Belviq lawsuits where patients have been diagnosed with cancer, including but not limited to the types listed above.
We encourage you to submit a Belviq Lawsuits Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About Uloric
The diet drug Belviq is being withdrawn from the US market because a Belviq safety clinical trial shows an increased occurrence of cancer cases. This February 2020 Belviq FDA Drug Safety Communication announced the Belviq recall, “FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market”, and noted that excess cases of pancreatic cancer, colon cancer, rectal cancer, and lung cancer were observed.
To read more of this article, click below:
The FDA approved Belviq as a weight-loss drug in 2012.
The Belviq safety clinical trial leading to this February 2020 Belviq recall is the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients – Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) clinical trial.
In connection with this Belviq recall we are investigating possible Belviq lawsuits involving for patients who have been diagnosed with cancer, including but not limited to:
Of course, we will continue to monitor the medical research for more information about the specific types of cancer cases associated with Belviq.[Read article in full at original source]
Earlier articles about Belviq by attorney Tom Lamb on the Side Effects Blog: